Table 2. Increased risk of Head and Neck Cancer comparing HIV-infectedindividuals with the general population.
| Study | Study Population | Type of Cancer | Standardized Incidence Ratios (SIRs) and (95%CIs) | |
|---|---|---|---|---|
| Overall | HIV-Transmission Subgroup# | |||
| Shiels et al. JAIDS 2009[4]& | Meta-analysis of developed countries (1980-2007) | Head and Neck | 2.0 (1.1-3.6) | --- |
| Simard et al. AIM 2010[34]ˆ | United States (1996-2006) | Oral Cavity and Pharynx | 1.8 (1.5-2.0) | --- |
| Silverberg et al. CEBP 2011[35**] | United States (1996-2008) | Oral Cavity and Pharynx | aRR*=1.4 (0.9-2.1) | --- |
| Shiels et al. JAIDS 2009[4]& | Meta-analysis of developed countries (1980-2007) | Oropharyngeal | 1.9 (1.2-2.5) | --- |
| Chatervedi et al. JNCI 2009[36] | United States (1980-2004) | Oropharyngeal | 1.6 (1.2-2.1) | MSM: 1.1 (0.7-1.8), IDU: 2.1 (1.3-3.2), Hetero:3.2 (1.6-5.7) |
| Clifford et al. JNCI 2005[37] | Switzerland (1985-2002) | Lip, Oral Cavity and Pharynx | 4.1 (2.1-7.4) | MSM: 2.0 (0.4-5.8), IDU: 13.7 (4.9-30.1), Hetero: 2.9 (0.3-10.5) |
| Frisch et al. JNCI 2000[38]ˆ | United States (1987-1996) | Tonsillar | 2.6 (1.8-3.8) | Hetero Men: 5.3 (1.1-15.4) |
&
Meta-analysis included three studies considering oropharynx cancers and four studies exploring head and neck cancer.
ˆ
Both studies used data from the US HIV/AIDS Cancer match study
*
Relative Risk based on an observational study controlling for potential risk factors such as tobacco and alcohol use
#
MSM= Men-who-have-sex-with-men, IDU=Injection drug user, Hetero=Heterosexual